



1.1 Table: Cumulative number of participants by type of care provider

Date	In cohort centers	In affiliated hospitals	In private practices	TOTAL
2008	13389	510	1733	15632
2009	13783	589	1877	16249
2010	14114	656	2001	16771
2011	14442	776	2117	17335
2012	14772	826	2222	17820
2013	15134	899	2319	18352
2014	15470	964	2416	18850
2015	15762	1041	2488	19291
2016	16060	1110	2573	19743
2017	16325	1171	2645	20141
2018	16576	1217	2707	20500
2019	16797	1275	2780	20852
2020	16918	1344	2833	21095
2021	17080	1421	2878	21379
2022	17243	1471	2905	21619

1.2 Table: Cumulative number of participants, by recruitment center

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2008	1987	1484	2466	913	488	2419	5875	15632
2009	2078	1560	2527	945	504	2514	6121	16249
2010	2149	1629	2567	972	515	2590	6349	16771
2011	2221	1735	2644	1006	525	2663	6541	17335
2012	2287	1787	2722	1048	534	2739	6703	17820
2013	2367	1855	2790	1076	557	2840	6867	18352
2014	2431	1920	2853	1105	568	2936	7037	18850
2015	2499	1984	2901	1134	580	3019	7174	19291
2016	2549	2058	2950	1159	600	3095	7332	19743
2017	2600	2116	3002	1194	615	3174	7440	20141
2018	2647	2169	3047	1216	626	3238	7557	20500
2019	2696	2214	3079	1245	636	3307	7675	20852
2020	2728	2254	3108	1265	642	3357	7741	21095
2021	2762	2285	3127	1286	649	3414	7856	21379
2022	2779	2326	3136	1310	665	3468	7935	21619

1.3 Table: Recruitment by center and year

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2008	107	51	68	27	20	81	232	586
2009	91	76	61	32	16	95	246	617
2010	71	69	40	27	11	76	228	522
2011	72	106	77	34	10	73	192	564
2012	66	52	78	42	9	76	162	485
2013	80	68	68	28	23	101	164	532
2014	64	65	63	29	11	96	170	498
2015	68	64	48	29	12	83	137	441
2016	50	74	49	25	20	76	158	452
2017	51	58	52	35	15	79	108	398
2018	47	53	45	22	11	64	117	359
2019	49	45	32	29	10	69	118	352
2020	31	40	27	19	6	51	65	239
2021	34	31	20	21	7	57	115	285
2022	18	41	12	26	16	57	81	251

1.4 Table: Participants under follow-up (i.e. seen in the respective year), by center

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2010	1143	841	1083	502	302	1196	3065	8124
2011	1157	937	1149	520	304	1225	3142	8416
2012	1178	958	1208	553	304	1268	3204	8660
2013	1220	1020	1229	563	318	1347	3275	8958
2014	1242	1047	1256	576	320	1414	3355	9199
2015	1294	1090	1266	592	322	1451	3405	9412
2016	1315	1135	1271	604	327	1477	3450	9565
2017	1303	1161	1263	622	336	1514	3458	9642
2018	1322	1167	1237	632	336	1524	3496	9706
2019	1353	1190	1234	651	336	1552	3490	9790
2020	1341	1191	1187	644	324	1559	3388	9621
2021	1336	1186	1141	658	327	1556	3420	9605
2022	1296	1176	1102	653	326	1571	3374	9483

1.5 Table: Cumulative number of participants by sex and transmission category, by most recent center

	BE	BS	GE	SG	TI	VD	ZH	total
Sex: Male	1600	1385	1574	761	435	1852	8174	15781
Sex: Female	743	616	719	324	184	939	2313	5838
Transmission category: Homosexual	755	744	875	302	197	971	4790	8634
Transmission category: Heterosexual	973	771	942	445	237	1267	2445	7080
Transmission category: Injection drug use	282	228	217	180	103	302	2029	3341
Transmission category: Inj. drug or sexual	173	107	112	68	57	119	885	1521
Transmission category: Other/unknown	160	151	147	90	25	132	338	1043

1.6 Table: Patients recruited in 2022, by age, sex, ethnicity, transmission category

	BE	BS	GE	SG	TI	VD	ZH	total
Age, Median (IQR)	44 (39-53)	40 (35-52)	35 (31-45)	38 (34-43)	44 (34-56)	43 (34-55)	39 (31-48)	40 (33-50)
Age: 18 to 24	1	1	0	1	1	0	3	7
Age: 25 to 44	9	22	9	20	7	31	53	151
Age: 45 to 64	8	16	3	5	8	23	22	85
Age: >65	0	2	0	0	0	3	3	8
Ethnicity: White	11	33	7	20	13	31	57	172
Ethnicity: Black	2	4	2	2	0	13	6	29
Ethnicity: Hispanic	2	3	2	2	3	5	12	29
Ethnicity: Asian	3	0	1	2	0	1	4	11
Sex: Male	13	37	10	20	13	42	75	210
Sex: Female	5	4	2	6	3	15	6	41
Transmission category: Homosexual	12	23	5	10	11	26	53	140
Transmission category: Hetersexual	4	10	4	6	4	24	19	71
Transmission category: Injection drug use	0	0	0	1	0	1	2	4
Transmission category: Inj. drug or sexual	0	0	0	1	0	1	0	2
Transmission category: Other/unknown	2	8	3	8	1	5	7	34



1.7 Table: Participants under follow-up in 2022 by age, sex, ethnicity, transmission category

	BE	BS	GE	SG	TI	VD	ZH	total
Age, Median (IQR)	54 (46-62)	54 (45-60)	55.5 (45-61)	54 (45-60)	57 (44-61)	52 (45-60)	54 (45-61)	54 (45-60)
Age: 18 to 24	4	5	7	3	2	6	16	43
Age: 25 to 44	296	280	222	169	51	428	790	2236
Age: 45 to 64	803	708	696	399	221	917	2109	5853
Age: >65	187	181	173	81	54	219	456	1351
Ethnicity: White	936	891	700	530	304	1064	2775	7200
Ethnicity: Black	237	166	275	79	8	395	225	1385
Ethnicity: Asian	37	41	72	16	10	57	182	415
Ethnicity: Hispanic	75	71	37	26	4	45	179	437
Ethnicity: Other/Unknown	5	5	14	1	2	9	10	46
Sex: Male	883	815	740	453	233	1029	2787	6940
Sex: Female	407	359	358	199	95	541	584	2543
Transmission category: Homosexual	515	497	448	212	127	620	2185	4604
Transmission category: Heterosexual	557	474	478	271	135	759	818	3492
Transmission category: Injection drug use	71	72	55	76	37	72	169	552
Transmission category: Inj. drug or sexual	48	33	34	29	16	35	81	276
Transmission category: Other/unknown	99	98	83	64	13	84	118	559

1.8 Table: Patients recruited in 2022, by HIV testing status

	BE	BS	GE	SG	TI	VD	ZH	total
Total	18	41	12	26	16	57	81	251
Diagnosis in 2022	9	20	1	15	6	24	35	110
Diagnosis before 2022	9	21	11	11	10	33	46	141
Days between diagnosis and registration, Median (IQR)	109 [44, 2324]	31 [8, 3658]	619 [307, 1239]	77 [18, 1988]	172 [12, 3480]	508 [15, 3521]	214 [24, 2073]	214 [16, 2663]
Documented negative test before 2022	11	18	5	11	4	26	53	128
No documented negative test before 2022	7	23	7	15	12	31	28	123

2.1 Table: CDC stages at recruitment and year (number of patients and median CD4 value)

	A				B				C				Total
	<200	200-500	>500	Median	<200	200-500	>500	Median	<200	200-500	>500	Median	
2017	33	117	176	519	10	6	9	352	14	19	13	386	397
2018	20	103	154	542	9	10	12	313	27	12	6	139	353
2019	27	104	147	523	11	6	5	215	26	15	7	186	348
2020	10	68	110	543	2	2	4	506	14	10	2	191	222
2021	14	76	143	579	4	2	2	207	11	10	3	204	265
2022	15	68	110	566	7	6	5	340	24	6	5	156	246

2.2 Table: CDC stages in active participants and year (number of patients and median CD4 value) *

	A				B				C				Total
	<200	200-500	>500	Median	<200	200-500	>500	Median	<200	200-500	>500	Median	
2017	113	1295	4327	669	67	572	1474	641	147	739	1243	558	9977
2018	84	1140	4543	699	58	539	1466	657	145	659	1291	583	9925
2019	87	1084	4589	705	48	514	1477	660	122	719	1249	574	9889
2020	66	1003	4600	715	42	461	1461	676	110	668	1259	580	9670
2021	66	1082	4604	704	38	460	1436	676	98	662	1235	584	9681
2022	67	994	4581	732	39	410	1366	690	99	615	1232	598	9403

* At the first CD4 assessment of the year

2.3 Table: The five most frequent AIDS defining events, number of diagnoses per year

	ESO	KSA	NHL	PCP	BPN	total
2017	13	5	4	19	2	43
2018	10	7	5	23	1	46
2019	14	12	8	11	4	49
2020	8	2	6	7	6	29
2021	7	2	6	11	4	30
2022	13	6	4	9	5	37

PCP = Pneumocystis pneumonia
ESO = oesophageal candidiasis
KSA = Kaposi sarcoma
NHL = Non-Hodgkin's lymphoma
BPN=Bacterial pneumonia

2.4 Table: Deaths during recent years, by CDC stage

	Stage A	Stage B	Stage C	Total	Patients seen
2017	25	20	40	85	9642
2018	26	17	29	72	9706
2019	22	19	18	59	9790
2020	17	13	37	67	9615
2021	27	18	44	89	9605
2022	20	19	28	67	9483

*Stage C indicates that the patients was at some point in stage C, not necessarily in the year of death: hierarchical category: stage C > stage B > stage A

2.5 Table: Reason of death

	HIV-related	Accident	Narcotics	Suicide	Other/Unknown	Total
2017	6	2	3	2	72	85
2018	3	2	2	6	59	72
2019	0	3	2	3	51	59
2020	2	1	2	4	58	67
2021	3	0	4	6	76	89
2022	0	1	0	4	63	67

Summary statistics - data report Version 5.3
Situation 2022/H2

3.1 Table: Treatment status at recruitment, by CD4 and year

	Treatment naive				On treatment				Treatment interrupted				Total
	<200	200-349	350-500	>500	<200	200-349	350-500	>500	<200	200-349	350-500	>500	
2017	49	41	50	84	8	15	29	104	0	2	4	11	397
2018	46	38	39	62	7	16	26	106	3	3	3	4	353
2019	50	46	35	72	13	18	22	82	1	2	1	6	348
2020	13	25	20	31	10	13	20	77	3	1	1	8	222
2021	23	28	31	53	5	14	13	88	1	2	0	7	265
2022	37	29	25	30	7	13	12	81	2	0	0	10	246

3.2 Table: Treatment status at recruitment, by HIV viral load and year

	Treatment naive (copies/ml)				On treatment (copies/ml)				Treatment interrupted (copies/ml)				Total
	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	
2017	37	21	105	60	151	8	5	1	8	0	1	0	397
2018	32	18	89	47	145	12	2	2	11	0	0	0	358
2019	34	15	86	67	116	12	6	2	8	2	1	0	349
2020	15	4	35	40	113	7	6	3	6	1	1	0	231
2021	35	11	59	34	106	13	2	1	6	1	3	1	272
2022	17	15	46	41	106	6	3	1	9	1	0	1	246

3.3 Table: Treatment status of participants under follow-up, by CD4 and year *

	Treatment naive				On treatment				Treatment interrupted				Total
	<200	200-349	350-500	>500	<200	200-349	350-500	>500	<200	200-349	350-500	>500	
2017	62	55	60	167	201	715	1598	6660	19	16	30	48	9631
2018	58	41	64	113	188	711	1390	7015	18	21	17	54	9690
2019	58	51	39	113	157	682	1459	7103	21	16	15	56	9770
2020	19	31	28	70	180	662	1353	7172	14	9	9	44	9591
2021	25	34	40	84	156	656	1411	7134	13	6	13	20	9592
2022	35	33	30	65	154	579	1359	7168	11	7	7	16	9464

*at first CD4 value

Summary statistics - data report Version 5.3
Situation 2022/H2

3.4 Table: Treatment status of participants under follow-up, by HIV viral load and year *

	Treatment naive (copies/ml)				On treatment (copies/ml)				Treatment interrupted (copies/ml)				Total
	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	
2017	58	20	177	88	8859	201	90	14	45	11	45	12	9620
2018	56	18	129	76	8953	224	106	10	46	15	39	10	9682
2019	46	14	108	94	9053	234	99	11	42	11	40	13	9765
2020	36	9	54	51	9019	270	73	13	28	9	25	14	9601
2021	50	15	70	50	8976	289	83	5	25	2	13	13	9591
2022	33	12	61	56	8837	342	72	12	12	4	16	9	9466

*at first viral load in the reporting year

3.5 Table: Participants under treatment by first, second and other regimen, median of the duration (days)

Treatment status	on first regimen		on second regimen		on third regimen		on fourth regimen		on fifth regimen		on ≥ sixth regimen		Total
	nb	median	nb	median	nb	median	nb	median	nb	median	nb	median	
2017	1275	1592	1456	1304	1196	1344.5	986	1250	867	1243	3403	1155	9183
2018	994	1282.5	1495	962	1273	943	995	913	896	923	3667	855	9320
2019	913	1087	1349	829	1343	752	1060	734	919	763	3834	716.5	9418
2020	856	1022	1277	908	1285	785	1104	716	906	799	3959	722	9387
2021	740	1212	1219	1096	1292	869	1185	792	908	840	3966	723	9310
2022	707	1120	1147	1142	1267	941	1201	906	947	899	3981	853	9250

3.6 The most frequent combinations: reference January 1st, 2023

REGIMEN	nb	%
BIC ETC TAF	2545	27
3TC DTG	1517	16
ETC RPV TAF	843	9
3TC ABC DTG	748	8
COB ETC EVG TAF	581	6
DTG ETC TAF	530	6
CABI RPV	198	2
ETC NVP TAF	197	2
3TC DOR TDF	191	2
3TC NVP	155	2
Total	80	

3.6.1 The most frequent combinations: reference July 1st, 2022

REGIMEN	nb	%
BIC ETC TAF	2423	26
3TC DTG	1276	14
3TC ABC DTG	913	10
ETC RPV TAF	899	10
COB ETC EVG TAF	707	8
DTG ETC TAF	584	6
ETC NVP TAF	207	2
COB DRV ETC TAF	168	2
3TC DOR TDF	166	2
3TC NVP	158	2
Total	82	

3.7 The most frequent initial regimens started in 2022

REGIMEN	nb	%
BIC ETC TAF	102	73
DTG ETC TAF	7	5
3TC DTG	6	4
COB DRV DTG ETC TAF	6	4
3TC ABC DTG	3	2
DTG ETC TDF	3	2
Total	90	

3.7.1 The most frequent initial regimens started in 2021

REGIMEN	nb	%
BIC ETC TAF	126	74
3TC DTG	13	8
DTG ETC TAF	5	3
3TC ABC DTG	4	2
DTG ETC TDF	4	2
3TC DOR TDF	2	1
Total	90	

3.7.2 The most frequent initial regimens started in 2020

REGIMEN	nb	%
BIC ETC TAF	91	71
3TC DTG	5	4
COB ETC EVG TAF	5	4
DRV ETC RTV TAF	4	3
DTG ETC TAF	4	3
3TC ABC DTG	3	2
Total	87	

3.7.3 The most frequent initial regimens started in 2019

REGIMEN	nb	%
BIC ETC TAF	99	41
DTG ETC TAF	64	27
COB ETC EVG TAF	15	6
3TC ABC DTG	10	4
COB DRV ETC EVG TAF	9	4
ETC RGV TDF	8	3
Total	85	

3.7.4 The most frequent initial regimens started in 2018

REGIMEN	nb	%
DTG ETC TAF	91	34
COB ETC EVG TAF	51	19
3TC ABC DTG	42	16
DTG ETC TDF	12	5
DRV ETC RTV TAF	10	4
DRV DTG ETC RTV TAF	9	3
Total	81	

3.7.5 The most frequent initial regimens started in 2017

REGIMEN	nb	%
3TC ABC DTG	85	27
COB ETC EVG TAF	70	22
DTG ETC TAF	58	18
DTG ETC TDF	23	7
ETC RPV TDF	17	5
EFV ETC TDF	11	3
Total	82	

3.8 The most frequent treatment switches in 2022 (newly started treatments of treatment-experienced patients in 2022 listed)

REGIMEN	nb	%
3TC DTG	521	31
BIC ETC TAF	391	23
CABI RPV	198	12
3TC DOR TDF	66	4
3TC ABC DTG	40	2
DTG ETC TAF	40	2
Total	74	

3.8.1 The most frequent treatment switches in 2021

REGIMEN	nb	%
BIC ETC TAF	542	32
3TC DTG	541	32
3TC DOR TDF	70	4
ETC RPV TAF	52	3
3TC ABC DTG	38	2
DTG ETC TAF	37	2
Total	75	

3.8.2 The most frequent treatment switches in 2020

REGIMEN	nb	%
BIC ETC TAF	1053	37
ETC RPV TAF	329	12
DTG ETC TAF	193	7
3TC ABC DTG	134	5
COB DRV ETC TAF	133	5
3TC NVP	118	4
Total	70	

3.8.3 The most frequent treatment switches in 2019

REGIMEN	nb	%
ETC RPV TAF	795	28
DTG ETC TAF	464	16
COB ETC EVG TAF	289	10
3TC ABC DTG	238	8
ETC RGV TAF	103	4
DTG ETC	75	3
Total	69	

3.8.4 The most frequent treatment switches in 2018

REGIMEN	nb	%
COB ETC EVG TAF	883	22
DTG ETC TAF	747	18
3TC ABC DTG	386	9
DRV ETC RTV TAF	292	7
ETC NVP TAF	276	7
ETC RGV TAF	133	3
Total	66	

3.8.5 The most frequent treatment switches in 2017

REGIMEN	nb	%
3TC ABC DTG	646	24
COB ETC EVG TAF	388	14
DTG ETC TDF	234	9
ETC RPV TDF	206	8
DRV ETC RTV TDF	75	3
DTG	73	3
Total	61	

3.9 The most frequent treatment switches in 2022/H2: From -> To

REGIMEN	nb	%
3TC ABC DTG -> 3TC DTG	178	11
BIC ETC TAF -> 3TC DTG	83	5
COB ETC EVG TAF -> 3TC DTG	75	5
COB ETC EVG TAF -> BIC ETC TAF	68	4
DTG ETC TAF -> 3TC DTG	56	3
BIC ETC TAF -> CABI RPV	53	3
3TC ABC DTG -> BIC ETC TAF	50	3
DTG ETC TAF -> BIC ETC TAF	41	3
3TC DTG -> CABI RPV	30	2
Total		39

3.10.1 Table: The five most frequently discontinued regimens in 2017 by reason, number°

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2017	DTG ETC TDF	2	2	3	28	7	14	9	68	136	178	444
2017	DRV ETC RTV TDF	1	0	0	31	2	15	15	45	142	146	392
2017	EFV ETC TDF	4	3	2	20	47	33	8	50	55	76	295
2017	ETC NVP TDF	2	1	3	10	0	9	3	23	37	160	245
2017	3TC ABC DTG	3	13	5	3	28	35	23	33	5	87	234

3.10.2 Table: The five most frequently discontinued regimens in 2018, by reason, number°

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2018	ETC RPV TDF	3	1	1	38	3	13	11	164	66	270	570
2018	3TC ABC DTG	2	7	0	1	16	41	28	41	16	100	252
2018	EFV ETC TDF	1	2	3	13	26	15	9	37	40	66	212
2018	DTG ETC TDF	0	1	0	12	0	9	6	25	18	50	120
2018	COB ETC EVG TAF	3	4	1	1	11	7	19	22	10	40	118

3.10.3 Table: The five most frequently discontinued regimens in 2019, by reason, number°

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2019	3TC ABC DTG	0	7	0	1	15	59	28	81	121	99	411
2019	DTG ETC TAF	1	0	1	2	7	8	26	59	100	47	251
2019	COB ETC EVG TAF	3	7	1	0	2	8	36	45	64	81	247
2019	EFV ETC TDF	2	0	1	7	13	5	5	41	32	49	155
2019	ETC RPV TDF	1	1	0	4	0	4	3	36	10	83	142

3.10.4 Table: The five most frequently discontinued regimens in 2020, by reason, number^o

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2020	3TC ABC DTG	1	6	0	1	3	22	29	105	101	76	344
2020	DTG ETC TAF	2	0	0	1	2	2	22	66	97	35	227
2020	COB ETC EVG TAF	1	2	1	3	2	4	12	19	41	59	144
2020	BIC ETC TAF	1	4	0	1	4	12	23	12	9	41	107
2020	DRV ETC RTV TAF	0	0	0	0	0	2	2	18	49	6	77

3.10.5 Table: The five most frequently discontinued regimens in 2021, by reason, number^o

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2021	3TC ABC DTG	1	3	1	0	4	14	14	79	167	71	354
2021	BIC ETC TAF	2	4	2	1	4	15	31	42	44	108	253
2021	COB ETC EVG TAF	2	1	0	1	0	4	9	39	101	68	225
2021	DTG ETC TAF	0	1	0	0	0	2	17	46	99	34	199
2021	ETC RPV TAF	1	1	0	0	1	5	8	20	20	30	86

3.10.6 Table: The five most frequently discontinued regimens in 2022, by reason, number^o

		Virological / Immunological	Toxicity					Patient wish	Physician decision	Simplification	Other	No. of regimen*
			GI	Liver	Kidney	CNS	Other					
2022	3TC ABC DTG	2	2	0	0	4	67	2	16	142	63	298
2022	BIC ETC TAF	4	3	1	2	15	24	17	14	95	94	269
2022	COB ETC EVG TAF	1	1	0	1	1	32	6	27	92	49	210
2022	DTG ETC TAF	0	2	0	0	1	5	4	14	80	40	146
2022	ETC RPV TAF	2	2	0	2	0	4	4	12	37	41	104

*one regimen can have several reason for discontinuation

^othe patients identity cannot be identified



4.1 Most frequent NRTI combinations: reference 1st January 2023

REGIMEN	nb	%
ETC TAF	5491	58
3TC	1760	19
ABC 3TC	937	10
ETC TDF	343	4
3TC TDF	205	2
TOTAL		93

4.1.1 Most frequent NRTI combinations: reference 1st July, 2022

REGIMEN	nb	%
ETC TAF	5653	60
3TC	1525	16
ABC 3TC	1141	12
ETC TDF	377	4
3TC TDF	185	2
TOTAL		94

4.1.2 Most frequent NRTI combinations: reference 1st January 2022

REGIMEN	nb	%
ETC TAF	5778	61
ABC 3TC	1315	14
3TC	1302	14
ETC TDF	413	4
3TC TDF	156	2
TOTAL		95

4.1.3 Most frequent NRTI combinations: reference 1st January, 2021

REGIMEN	nb	%
ETC TAF	5959	61
ABC 3TC	1733	18
3TC	795	8
ETC TDF	486	5
3TC TDF	105	1
TOTAL		94



4.1.4 Most frequent NRTI combinations: reference 1st January, 2020

REGIMEN	nb	%
ETC TAF	5710	58
ABC 3TC	2228	23
ETC TDF	633	6
3TC	364	4
ETC	196	2
TOTAL		94

4.1.5 Most frequent NRTI combinations: reference 1st January 2019

REGIMEN	nb	%
ETC TAF	4785	49
ABC 3TC	2802	29
ETC TDF	1081	11
3TC	221	2
ETC	191	2
TOTAL		94

4.1.6 Most frequent NRTI combinations: reference 1st January 2018

REGIMEN	nb	%
ETC TAF	3206	33
ABC 3TC	2986	31
ETC TDF	2357	24
3TC	230	2
AZT 3TC	103	1
Total		91



4.2 Number of different substances: Median number of substances, and nr of patients taking 1, 2, 3, 4, 5, >5 substances

	median	1	2	3	4	5	>5
2017	3 [3,4]	110	272	6553	2470	347	77
2018	3 [3,4]	106	335	6578	2398	334	68
2019	3 [3,3]	101	592	6755	1997	323	63
2020	3 [3,3]	83	912	6576	1674	322	62
2021	3 [3,3]	83	1437	6284	1335	293	51
2022	3 [3,3]	125	2084	5894	1033	267	45

5.1 Table: Status of HBV infection of participants under follow-up having a HBV screening result, by reference date*

	No HBV infection (AntiHBc negativ)	HBV infection (AntiHBc positive)	missing AntiHBc	Total
2017	5310 (55.1%)	3872 (40.2%)	460 (4.8%)	9642 (100%)
2018	5378 (55.4%)	3832 (39.5%)	496 (5.1%)	9706 (100%)
2019	5460 (55.8%)	3785 (38.7%)	545 (5.6%)	9790 (100%)
2020	5420 (56.4%)	3674 (38.2%)	521 (5.4%)	9615 (100%)
2021	5440 (56.6%)	3591 (37.4%)	574 (6%)	9605 (100%)
2022	5411 (57.1%)	3488 (36.8%)	584 (6.2%)	9483 (100%)

*Under follow-up means a documented follow-up visit in the reference year

5.2 Table: HBV infection by centre

	BE	BS	GE	SG	TI	VD	ZH	Total
2017	510	472	610	234	133	633	1291	3883
2018	524	463	580	238	134	641	1268	3848
2019	520	463	567	246	129	625	1246	3796
2020	508	447	538	248	122	619	1192	3674
2021	505	434	510	246	120	610	1166	3591
2022	478	423	491	235	115	608	1138	3488

6.1 Table: Status of HCV infection: participants with an anti-HCV screening result, under follow-up at the reference date

	HCV Ab negative	HCV Ab positive			Unknown HCV Ab	Total
		replicating	not replicating	unknown replication		
2017	7890	411	1147	86	108	9642
2018	8015	277	1264	59	91	9706
2019	8117	214	1310	53	96	9790
2020	8046	189	1274	40	66	9615
2021	8051	181	1255	35	83	9605
2022	7996	65	1301	17	104	9483

6.2 Table: The most frequent HCV genotypes among participants with a replicating HCV infection, under follow-up

	1	2	3	4	other	unknown	total
2017	172	6	72	83	2	76	411
2018	122	3	45	48	0	59	277
2019	85	2	28	39	0	60	214
2020	64	2	26	32	0	65	189
2021	66	2	21	27	0	65	181
2022	21	0	8	11	0	25	65

6.3 Table: HCV treatment status of participants, under follow-up at the reference date*

	Treatment ongoing	Treatment terminated
2017	60	205
2018	13	150
2019	3	51
2020	5	23
2021	0	17
2022	0	5

*Update made for all years, due to additional data available